The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia

Sherif A Nasef*, A. Aziz Shaaban, Joaquin Mould-Quevedo and Tarek A Ismail

Abstract

Background: Cyclooxygenase (COX)-2 inhibitors including celecoxib are as effective as non-selective non-steroidal anti-inflammatory drugs (ns-NSAIDs) in the treatment of osteoarthritis (OA) and have less gastrointestinal toxicity. Although they are associated with higher treatment costs, COX-2 inhibitors may simultaneously reduce costs associated with adverse events, hence, their overall economic benefit should be assessed.

Objective: To evaluate the incremental cost effectiveness ratio (ICER) of celecoxib versus ns-NSAIDs, with/without proton-pump inhibitor (PPI) co-therapy, for managing OA in Saudi Arabian subjects aged ≥65 years.

Methods: The National Institute for Health and Care Excellence health economic model from the UK, updated with relative risks of adverse events using CONDOR trial data, was adapted. Patients received celecoxib or ns-NSAIDs, with/without omeprazole. The effectiveness measure was quality-adjusted life years (QALYs) gained per patient. The analysis was conducted from the patient’s perspective. Frequencies of resource use for adverse events were based on data collected in July 2012 from seven private hospitals in Jeddah, Saudi Arabia. Probabilistic sensitivity analysis was performed to construct cost-effectiveness acceptability curves (CEACs).

Results: Over a 6-month treatment duration, QALYs gained per patient were higher with celecoxib (0.37) and celecoxib plus PPI (0.40) versus comparators. Ibuprofen plus PPI showed the lowest expected cost per patient (US$1,314.50 versus US$1,422.80 with celecoxib plus PPI and US$1,543.50 with celecoxib). Celecoxib plus PPI was the most cost-effective option with an ICER of US$1,805.00, followed by celecoxib (ICER, US$7,633.33) versus ibuprofen plus PPI. Over 2- and 5-year treatment durations, celecoxib plus PPI, and celecoxib, showed higher QALYs gained/patient and lower ICERs versus comparators. These ICERs are <1 gross domestic product/capita in Saudi Arabia in 2013 (US$25,961).

CEACs over 6 months’ treatment showed a significantly higher likelihood that celecoxib plus PPI and celecoxib alone would be more cost effective versus comparators once the willingness to pay is over US$2,000.00.

Conclusion: After considering new adverse event risks, celecoxib with/without PPI co-therapy was deemed very cost effective for medium- and long-term use in Saudi Arabian OA patients aged ≥65 years.

Keywords: Celecoxib; Non-steroidal anti-inflammatory drugs; Saudi Arabia; Cost effectiveness; Osteoarthritis
Background
Osteoarthritis (OA) is a widely prevalent condition, which is associated with significant morbidity and quality-of-life issues. According to the World Health Organization (WHO), up to 40 % of the population aged >70 years suffers from OA, with 80 % of patients having some form of movement limitation and 25 % having problems in performing their daily activities [1].

Studies show that pain is an important cause of disability and reduced function in OA patients [2, 3]. Paracetamol and non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of pharmacological management for controlling pain and stiffness in OA [4]. Oral NSAIDs are recommended in patients who do not respond to full-dose paracetamol. However, NSAIDs are associated with adverse effects on the gastrointestinal (GI), cardiovascular (CV) and renal systems. Furthermore, the risk of GI bleeding increases with age, and in subjects with stomach ulcers and bleeding problems [5]. Some cyclooxygenase (COX)-2 inhibitors such as celecoxib are associated with less GI and CV adverse reactions than non-selective NSAIDs (ns-NSAIDs) [5].

To reduce the risk of GI toxicity, the 2008 National Institute for Health and Care Excellence (NICE) Clinical Guideline for managing OA in adults recommends co-prescribing both selective and ns-NSAIDs with proton-pump inhibitors (PPIs) [5]. Celecoxib versus Omeprazole and Diclofenac in patients with Osteoarthritis and Rheumatoid arthritis (CONDOR) was a landmark trial that was published after the NICE Clinical Guideline. It showed that the proportion of patients developing clinically significant GI events throughout the GI tract was significantly lower among those receiving celecoxib versus the ns-NSAID diclofenac plus omeprazole (hazard ratio [HR], 4.3 in favour of celecoxib; 95 % confidence interval [CI], 2.6 to 7.0; p < 0.0001) [6].

According to the NICE Clinical Guideline for managing OA in adults, the choice of NSAID and PPI should be determined by the cost of these agents [5]. A health economic model developed by NICE demonstrated that treatment with celecoxib plus PPI was more cost-effective than that with diclofenac plus PPI [5]. Furthermore, it has been shown that it is cost effective to co-prescribe a PPI with a COX-2 inhibitor even in patients who have low risk of GI adverse events [5, 7].

There are sparse data on the epidemiology of OA in Saudi Arabia. A study conducted in 1995 among 5,894 Saudi Arabian adults found OA in 13 % of the subjects. In line with global data, the prevalence of OA was high in the elderly population (30.8 % in those aged 46–55 years and 60.6 % in those aged 66–75 years) [8]. Another recent study found that elderly Saudi patients with OA had significantly higher pain scores and physical disability than those without OA, leading to a negative impact on their quality of life [9]. Clearly, there is an important role for pain medications in the management of OA in Saudi Arabia.

The Saudi Ministry of Health is the major government provider and financer of healthcare services in Saudi Arabia, responsible for 60 % of the total health services in the country; other government bodies, including specialist referral hospitals, security forces and army medical services, and school health units of the Ministry of Education, account for another 20 % [10]. Private sector healthcare services make up the remaining 20 %, important particularly in cities and large towns. As services in government facilities are provided free-of-charge, a considerable cost pressure is exerted on the national government [10]. This prompted the establishment of a cooperative health insurance scheme in 1999. Cooperative health insurance is applicable to Saudi citizens and expatriates in the private sector, in which employers are mandated to pay for employees’ health coverage costs [10]. From one insurance company in 2004, the providers of cooperative health insurance now number 25 companies.

Data on the cost effectiveness of drugs for OA will be invaluable to health policy makers, insurance providers and healthcare professionals, allowing better informed decision-making when choosing treatments to fund or utilize.

The objective of this study was to determine the cost effectiveness of celecoxib versus ns-NSAIDs, with and without PPI co-therapy, for managing OA in subjects aged ≥65 years in Saudi Arabia.

Methods
This cost effectiveness analysis (CEA) was performed according to the recommendations described by NICE [11]. The primary outcome of cost effectiveness was quality-adjusted life years (QALYs). A patient perspective was adopted for the analysis as cost of treatment is borne by patients in Saudi Arabia.

Comparators
Data from five large randomized controlled trials that report GI and CV events associated with NSAID use in predominantly OA patients were used to obtain adverse event data for this analysis. These included Celecoxib Long-term Arthritis Safety Study (CLASS; celecoxib, ibuprofen and diclofenac) [12], the Multinational Etoricoxib and Diclofenac Arthritis Long-term study (MEDAL; etoricoxib and diclofenac) [13], the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET; lumiracoxib, naproxen and ibuprofen) [14, 15], the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerance and Effectiveness trial (EDGE; etoricoxib and diclofenac) [16] and CONDOR [6]. Of these, CLASS and MEDAL also included some patients with rheumatoid arthritis (RA). However, the relative risk of adverse events was considered to be
similar in subjects with OA and RA as there is no evidence to suggest that rates of drug-induced adverse events are related to the type of arthritis [7]. These studies permit comparison between COX-2 inhibitors (celecoxib and etoricoxib) and ns-NSAIDs (diclofenac, ibuprofen and naproxen). In this CEA, we compared the cost effectiveness of celecoxib (200 mg OD) versus ibuprofen (400 mg TID), diclofenac (50 mg TID), and etoricoxib (30 mg OD), with and without omeprazole co-therapy (20 mg OD). These NSAIDs were chosen as there are enough data from clinical studies to allow reliable comparisons. Furthermore, these are the most commonly used agents for treating OA in Saudi Arabia [17]. Paracetamol was not included in the analysis as it is considered to have inferior efficacy compared with NSAIDs [18] and, thus, rarely used for managing pain in Saudi OA patients.

**Model design**

The CEA health model has been described elsewhere [11]. As such, the NICE health economic model developed in 2008 and updated by Brereton et al. with relative risk data for adverse events from the CONDOR trial was adapted for this CEA [19]. It is in the form of a Markov model with a 3-month cycle, which assumes that each patient experiences only one GI or CV event per cycle; patients may experience multiple GI and CV events over the whole time horizon (Fig. 1). Treatment duration of 6 months was adopted in the base case version of the model. The possible adverse events considered by the model included GI symptoms, symptomatic ulcer, complicated GI events, stroke, myocardial infarction and heart failure. Patients could experience multiple events at multiple points in time. The authors had previously utilized this model to evaluate the cost-effectiveness of celecoxib versus ns-NSAIDs plus PPI for treating OA in Algeria [20].

**Patient populations**

The model estimated results for patients with OA aged ≥65 years. This age group was selected based on the data suggesting a 2.96-times greater risk of developing a symptomatic or complicated GI event in subjects aged ≥65 years [21].

**Adverse events**

Adverse event data were derived from the CLASS, MEDAL, TARGET, EDGE and CONDOR studies [6, 12–16, 19, 20]. Dose adjustments were performed in accordance with dosing regimens followed in Saudi Arabia. The overall rates of adverse events observed with different NSAIDs in these studies are shown in Table 1. Data from this table were used to perform probabilistic sensitivity analyses. Data for relative risk for each adverse event were taken from the Brereton study, which pooled data from the CLASS and CONDOR studies (Fig. 2) [19].

**Costs**

The analysis included costs incurred by patients for drug acquisition, treatment of adverse events and physician visits. The costs of treating adverse events included those...
associated with hospitalization, outpatient procedures and consultations, and co-prescription of PPIs (Table 2). These were estimated from data collected in July 2012 from seven private hospitals in Jeddah, Saudi Arabia. Daily treatment costs of drugs were obtained from the Saudi Ministry of Health drug list 2013 (Table 3) [22].

It was assumed that patients made one consultation per adverse event, with patients with dyspepsia or symptomatic ulcer needing outpatient management only. Hospitalization costs were estimated in patients with complicated GI event, myocardial infarction, stroke and heart failure; the duration of hospitalization was based on the type and severity of the adverse event.

Costs were estimated for treatment over a period of 6 months, 2 years and 5 years. All daily cost data were expressed in 2013 prices and converted to US$ using an average 2013 exchange rate (1 US$ = 3.75 Saudi Riyal). A discount rate of 3% was used for costs and benefits, in line with the WHO guide for conducting a CEA [23].

**QALY data**

The utility scores were taken from the EQ-5D and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores used in the NICE economic model [7]. EQ-5D is a standardized instrument used to measure health outcomes while WOMAC is a 24-item instrument validated for assessing pain, stiffness, and physical function in OA patients, widely used for evaluating outcomes in OA clinical trials. There was no evidence to suggest any correlation between different drug doses and drug efficacy. Thus, for this study, equal utility weights were assumed for ns-NSAIDs and COX-2 inhibitors in patients who did not experience adverse events. Utility weights for adverse events were based on data from the literature [24, 25].

**Cost-effectiveness analyses**

The expected costs and QALY gains associated with eight treatment options were calculated for treatment administered over 6 months, 2 years and 5 years using deterministic analysis. Incremental cost effectiveness ratios (ICERs), defined as the additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option, were calculated for each treatment duration.

**Sensitivity analyses**

To assess the robustness of the model, probabilistic sensitivity analysis was performed using Monte Carlo simulations by generating 10,000 second-order iterations of

---

### Table 1 Overall rates of adverse events observed in CONDOR, MEDAL, CLASS, EDGE and TARGET [6, 11–15]

| Treatment options | Overall rates of adverse events/patient (% ± SD) |
|-------------------|-----------------------------------------------|
|                   | GI symptoms | Symptomatic ulcer | Complicated GI event | Myocardial infarction | Stroke | Heart failure |
| Diclofenac        | 21.30 (±0.9) | 0.14 (±0.02) | 0.07 (±0.01) | 0.09 (±0.01) | 0.06 (±0.01) | 0.02 (±0.01) |
| Ibuprofen         | 12.72 (±0.54) | 0.20 (±0.09) | 0.08 (±0.04) | 0.15 (±0.11) | 0.06 (±0.04) | 0.09 (±0.12) |
| Celecoxib         | 12.45 (±0.46) | 0.09 (±0.04) | 0.05 (±0.03) | 0.15 (±0.10) | 0.02 (±0.02) | 0.04 (±0.06) |
| Etoricoxib        | 10.40 (±0.43) | 0.14 (±0.02) | 0.05 (±0.03) | 0.10 (±0.01) | 0.06 (±0.01) | 0.02 (±0.01) |

GI, gastrointestinal; SD, standard deviation

---

**Fig. 2** Relative risks for adverse events according to estimated treatment effects [18]. GI, gastrointestinal
the analysis. For each iteration, a different set of values was used for the parameters selected for the analysis. The 10,000 iterations generated costs and QALY results which were used to construct a cost-effectiveness acceptability curve (CEAC) that summarized the evidence in favour of a treatment arm versus comparators, and demonstrated the confidence with ICERs obtained over a range of thresholds of acceptability.

**Results**

**Base case analysis**

Base case analysis showed that the estimated QALY gain per patient was highest with celecoxib plus PPI (0.40) followed by etoricoxib plus PPI (0.38) and celecoxib alone (0.37) versus all comparators. The expected cost of treatment per patient was lowest with ibuprofen plus PPI (US$ 1,314.50), followed by celecoxib plus PPI (US$ 1,422.80) and celecoxib (US$ 1,543.50) (Table 4).

The most cost effective treatment over a 6-month period was celecoxib plus PPI, with an incremental cost of US$ 108.30 and an incremental QALY gain of 0.06 resulting in an ICER of US$ 1,805.00 versus ibuprofen plus PPI (Table 4). When celecoxib plus PPI was excluded from the base case analysis, celecoxib alone was the most cost effective intervention, with an incremental cost of US$ 229.00 and an incremental QALY gain of 0.03 giving an ICER of US$ 7,633.33 versus ibuprofen plus PPI (data not shown).

The ICERs for both celecoxib alone and celecoxib plus PPI are <1 gross domestic product (GDP) per capita in Saudi Arabia in 2013 (US$ 25,961) [26], and thus considered very cost effective by the WHO-established Commission on Macroeconomics and Health [27]. Thus, celecoxib alone and celecoxib plus PPI are very cost effective treatments for Saudi Arabian OA subjects aged ≥65 years.

The other treatment options were either more expensive or less effective and, therefore, excluded by simple dominance.

**Sensitivity analyses**

Analyses over 2- and 5-year treatment durations found that celecoxib plus PPI and celecoxib alone were consistently associated with higher incremental QALY gain per patient and decreasing ICERs versus comparators. Moreover, ICERs associated with celecoxib plus PPI remained lower than those of comparators across all treatment durations, making it the most cost-effective intervention for medium- and long-term use in elderly OA patients in Saudi Arabia (Tables 4, 5 and 6).

When celecoxib plus PPI was excluded from the analysis, celecoxib alone was the most cost effective option for treating OA in Saudi Arabia over all treatment durations (data not shown). Over 2- and 5-year treatment durations, the increased costs per patient with celecoxib alone (US$ 4,716.80 and US$ 7,407.10, respectively) were associated with highest QALYs gained per patient versus all comparators (1.24 QALYs and 2.50 QALYs, respectively), giving ICERs of US$ 3,943.85 and US$ 2,096.32, respectively, versus ibuprofen plus PPI (data not shown).

We believe this is an important finding relevant for consideration in situations where PPIs may not be available. Of note, the ICERs for long-term treatment with celecoxib plus PPI and celecoxib alone were within the prescribed 1 GDP per capita for Saudi Arabia.

The robustness of findings was further confirmed with CEACs for the base case analysis. The probability that a treatment option would be cost effective was plotted against the Y-axis and the threshold cost effectiveness (the amount of money that one is willing to spend to gain one year of life) on the X-axis. Our analysis found a significantly higher likelihood that celecoxib plus PPI...
and celecoxib alone would be more cost effective versus comparators once the willingness to pay is over US$ 2,000.00 (data not shown).

**Discussion**

After considering adverse event data from five large trials including predominantly OA patients, this CEA found that, over a 6-month treatment duration, celecoxib is more cost-effective than ns-NSAIDs, with and without PPI co-therapy, for treating Saudi Arabian OA patients aged ≥65 years. Celecoxib plus PPI remained the most cost-effective intervention even over a 5-year treatment duration. Analyses over 6-month, 2-year and 5-year treatment durations found that, next to celecoxib plus PPI, celecoxib alone had the highest QALYs gained/patient and was the most cost effective intervention. At a cost effectiveness threshold of 1 GDP per capita in Saudi Arabia, celecoxib plus PPI, as well as celecoxib alone, were highly cost effective for medium- and long-term treatment of OA in elderly Saudi Arabian patients.

Two recent economic analyses used the same economic model and clinical data and arrived at conclusions that align with our findings. A recent CEA performed in Algeria found that celecoxib plus PPI and celecoxib alone were associated with the highest QALYs gained per patient versus ns-NSAIDs with and without PPI co-therapy over 6-month and 5-year time horizons. The authors concluded that these were the most cost effective treatments for elderly OA patients in Algeria [20]. Similarly, Brereton et al. also showed that celecoxib plus PPI was more cost effective than diclofenac plus PPI for treating OA in the UK [19].

Could these results not have been extrapolated to the Saudi Arabian setting? Indeed, OA management varies very minimally across countries – physicians in the Middle East follow the same international treatment guidelines as doctors in Europe, and patients will present, on average, the same responses to treatment; this is why we decided to use the NICE health economic model for this CEA, the structure of which corresponds specifically to the management of OA patients. However, it would have been inaccurate to extrapolate Algerian or UK economic model outcomes to the Saudi Arabian setting as prices, treatment costs, treatment pathways, and other variables

| Therapy            | Cost/patient (US$) | QALYs gained/patient | ICER (ΔC/ΔE) | Comparator                        |
|--------------------|--------------------|-----------------------|--------------|-----------------------------------|
| Ibuprofen + PPI    | 1,314.50           | 0.34                  | 3,866.18     | No treatment                      |
| Celecoxib + PPI    | 1,422.80           | 0.40                  | 1,805.00     | Ibuprofen + PPI                   |
| Celecoxib*         | 1,543.50           | 0.37                  |              | Dominated                         |
| Diclofenac + PPI*  | 1,565.30           | 0.35                  |              | Dominated                         |
| Ibuprofen*         | 1,608.20           | 0.28                  |              | Dominated                         |
| Diclofenac*        | 1,695.00           | 0.31                  |              | Dominated                         |
| Etoricoxib + PPI   | 1,749.00           | 0.38                  |              | Dominated                         |
| Etoricoxib         | 1,839.10           | 0.36                  |              | Dominated                         |

*Simple dominance: Another option is less expensive and more effective

ICER: incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year

ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option
are different. Thus, the results we present are unique to Saudi Arabia and, to our knowledge, cannot be obtained from other published sources.

The findings of this CEA are in agreement with several economic analyses that show celecoxib to be more cost effective than ns-NSAIDs given with and without gastro-protective agents to patients with OA and RA [28–33]. Two economic analyses performed in Hong Kong found celecoxib to be more cost-effective than ns-NSAIDs with or without PPI co-therapy in OA and RA subjects with high GI risk [29, 32]. According to Latimer et al., co-prescription of PPI with a COX-2 inhibitor rather than with an ns-NSAID was cost effective even in young subjects who have low GI risk [7]. In another study, Zabinski et al. found that co-prescription of ns-NSAIDs with gastroprotective agents was cost effective in high-risk patients, and the benefits accrued by using celecoxib in moderate-to-high risk patients served to offset the high costs of using celecoxib to treat low-risk patients [33]. However, this finding may be more relevant in health systems where the cost of treatment is borne by the government rather than patients.

This study has several strengths. Unlike most studies that restricted the analysis to a treatment period of 6 months, we estimated costs and benefits over 5 years of treatment. This is very relevant in OA as it is a chronic disease for which patients need long-term NSAID treatment, resulting in cumulative risk of NSAID-induced gastropathy [30]. Notably, in this model, patients with previous events were considered to have a higher likelihood of presenting with new events. Celecoxib plus PPI was the most cost effective intervention despite considering CV adverse events such as myocardial infarction, stroke and heart failure in the analysis. This is an important consideration as the elderly population included in this study may also be suffering from comorbid CV conditions. Furthermore, they may also be on prophylactic aspirin, though we did not model the increased risk of bleeding arising from aspirin therapy in this analysis. Thus, the incremental benefits from celecoxib plus PPI may well be underestimated in the current analysis.

This analysis also has several limitations. We did not stratify the estimated costs and benefits according to the age or risk category of patients. Loyd et al. found that the ICERs decreased when their analysis considered the increased risk of peptic ulcer bleeding with advancing age [30]. This analysis did not consider the indirect costs of OA which are known to be significant and comparable with direct costs [34]. Adverse event data were pooled from five randomized controlled trials rather than real-life situations; however, these were large studies conducted in multiple centres across several countries, and may, therefore, be considered to reflect real-life incidence of adverse events.

Some limitations are related to the economic model used for the analysis, which may have underestimated the potential benefits of treatment. For example, the model assumed that patients were maintained on the same treatment throughout the study period, whereas, in reality, patients often switch treatments due to lack of efficacy or drug intolerance. In addition, the model assumed continuous use of a drug when intermittent NSAID treatments are also known to be effective for some OA patients [30]. Only differences in GI and CV adverse event rates were modelled, with no consideration of the costs arising from any possible differences in effectiveness of the different treatments. Of note, the differences in adverse event rates derived from the randomized controlled trials were small, introducing an element of uncertainty to the sensitivity analyses.

**Conclusions**

After considering new adverse risks, this CEA found that celecoxib plus PPI and celecoxib alone are very cost effective options for Saudi Arabian OA patients aged ≥65 years. Celecoxib plus PPI was the most dominant treatment over 6-month and 5-year periods, making it the most cost-effective option for medium- and long-term management of elderly OA patients in Saudi Arabia.

### Table 6 Cost effectiveness analysis over 5-year treatment duration

| Therapy            | Cost/patient (US$) | QALYs gained/patient | ICER (ΔC/ΔE) | Comparator |
|--------------------|--------------------|----------------------|--------------|------------|
| Celecoxib + PPI    | 6,705.80           | 2.68                 | 2,502.16     | No treatment |
| Ibuprofen + PPI*   | 7,008.80           | 2.31                 | Dominated    | -          |
| Celecoxib*         | 7,407.10           | 2.50                 | Dominated    | -          |
| Diclofenac + PPI*  | 7,930.50           | 2.39                 | Dominated    | -          |
| Diclofenac*        | 10,140.20          | 2.05                 | Dominated    | -          |
| Ibuprofen*         | 10,586.10          | 1.83                 | Dominated    | -          |
| Etoricoxib + PPI   | 11,574.20          | 2.64                 | Dominated    | -          |
| Etoricoxib*        | 12,983.90          | 2.48                 | Dominated    | -          |

*Simple dominance: Another option is less expensive and more effective
ICER, incremental cost-effectiveness ratio; PPI, proton-pump inhibitor; QALY, quality-adjusted life year
ICER: additional cost per patient achieving a unit of effectiveness compared with the next less costly, non-dominated option
Competing interests
SN has no financial or other relationships to declare. AS and TI are full time employees of Pfizer Inc. JM was a full time employee of Pfizer Inc.

Authors’ contributions
SN was responsible for design of the study, acquisition of data, analysis and interpretation of the results, drafting and critically revising the manuscript. AS was responsible for design of the study, acquisition of data, interpretation of the results, drafting and critically revising the manuscript, and acquiring funding. JM was responsible for concept and design of the study, interpretation of the results, and drafting and critically revising the manuscript. TI was responsible for concept and design of the study, interpretation of the results, and drafting and critically revising the manuscript. All authors read and approved the final manuscript.

Acknowledgements
The authors would like to thank Dr Pradnya Kulkarni and Dr Jose Miguel (Awil) Curameng of MIMS (Hong Kong) Limited for providing medical writing & editing support.

Received: 23 February 2015 Accepted: 22 May 2015

Published online: 11 June 2015

References
1. World Health Organization. The world health report. 50 facts. http://www.who.int/whr/1997/media_centre/50facts/en/. Accessed 12 May 2014.
2. Moskowitz RW. The burden of osteoarthritis: clinical and quality-of-life issues. Arthritis Care. 2009;5(22):32–39.
3. Jordan J, Luta G, Dragomir A, Hochberg M, Fryer J. Knee pain and knee osteoarthritis severity in self-reported task specific disability: the Johnston County Osteoarthritis Project. J Rheumatol. 1997;24:344–9.
4. Hochberg MC, Altman RD, Appt KT, Benkahlit M, Guayatt G, McGowan J, et al. American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res. 2012;64:465–74.
5. National Collaborating Centre for Chronic Conditions: Osteoarthritis: National clinical guideline for care and management in adults. London: Royal College of Physicians. 2008. http://www.nice.org.uk/guidance/cg59/resources/guidance-osteoarthritis-the-care-and-management-of-osteoarthritis-in-adults-pdf. Accessed 12 May 2014.
6. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376:173–9.
7. Latimer N, Lord J, Grant RL, O’Mahony R, Dickson J, Conaghan PG, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538.
8. Al-Arfaj AS, Alballa SR, Al-Saleh SS, Al-Dalaan AM, Bahabry SA, Mousa MA, et al. Knee osteoarthritis in Al-Qaseem, Saudi Arabia. Saudi Med J. 2003;24:291–3.
9. Alrshud AA, El-Sobely SB, Haoz AF, Al-Ahadeeb A. Impact of knee osteoarthritis on the quality of life among Saudi elders: A comparative study. Saudi J Sports Med. 2013;13:10–6.
10. Almalki M, Fitzgerald G, Clark M. Health care system in Saudi Arabia: an overview. East Mediterr Health J. 2011;17:764–93.
11. National Collaborating Centre for Chronic Conditions. Appendices D. Osteoarthritis: National clinical guidelines for care and management in adults. London: Royal College of Physicians. 2008. http://www.ncbi.nlm.nih.gov/books/NBK48094/pdf/TOC.pdf. Accessed 12 May 2014.
12. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis the CLASS study. A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–55.
13. Cannon CP, Curtis SP, Fitzgerald GA, Krum H, Kaur A, Bolognese JA, et al. MEDAL Steering Committee. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinationa l Etoricoxib and Diclofenac: Arthritis Longterm (MEDAL) programme: a randomised comparison. Lancet. 2006;368:177–81.
14. Farhoun ME, Kirchner H, Harrington RA, Rubland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364:675–84.
15. Schnitzer TJ, Burmester GR, Myller E, Hochberg MC, Doherty M, Ehrism E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665–74.
16. Baraf HS, Fuentesalba C, Greenwald M, Breslizki J, O’Brien K, Soffer B, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol. 2007;34:408–20.
17. IMS Saudi Arabia. Saudi Arabian sales data. June 2013.
18. Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;(1):CD004257.
19. Bereton N, Winn B, Akehurst R. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial. J Med Econ. 2012;15:465–72.
20. Hammourouai N, Khamel SA, Mould-Quevedo J, Ismail TA. The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors for treating osteoarthritis in Algeria. JHEOR. 2013;1:184–99.
21. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;331:1310–6.
22. Saudi Arabia Ministry of Health. Drug List 2013. http://www.sfda.gov.sa/en/Documents/Human_Drug_List_May_2014_V1_web.xls. Accessed 12 May 2014.
23. World Health Organization. Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. http://www.who.int/choice/publications/p_2003_generalised_cea.pdf. Accessed 12 May 2014.
24. Maertel A, Kain M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with osteoarthritis or rheumatoid arthritis, Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCHOHTA); 2002. Technology report no 23.
25. National Institute for Health and Clinical Excellence. Prevention. Management of hypertension in adults in primary care. final update. London: NICE. 2006.
26. World Bank. GDP per capita (current US$). http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed 23 February 2015.
27. World Health Organization. Choiceing Interventions that are Cost Effective (WHO-CHOICE). Cost-effectiveness thresholds. http://www.who.int/choice/costs/CER_levels/en/index.html. Accessed 12 May 2014.
28. Chancellors N, Hunsche E, de Cruz E, Sarsam F. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics. 2001;19 Suppl 1:59–75.
29. Lee KK, You JH, Ho JT, Suen BY, Yung MY, Lau WH, et al. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthrits in patients at risk of ulcer disease. Aliment Pharmacol Ther. 2003;18:217–22.
30. Loyd M, Rublee D, Jacobs P. An economic model of long-term use of celecoxib in patients with osteoarthritis. BMC Gastroenterol. 2007;7:25.
31. Turajane T, Chaweevanakorn U, Sunghkun P, Larbphiboonpong V, Wongbunrak N. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice. J Med Assoc Thai. 2012;95 Suppl 10:598–104.
32. You JH, Lee KK, Chan TY, Lau WH, Chan FK. Arthrits treatment in Hong Kong–cost analysis of celecoxib versus conventional NSAIDs, with or without gastroprotective agents. Aliment Pharmacol Ther. 2002;16:2089–96.
33. Zabinski RA, Burke TA, Johnson J, Lavie F, Fitzsimons C, Trettak R, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics. 2001;19 Suppl 1:49–58.
34. Hunsche E, Chancellors N, Bruce N. The burden of arthrits and nonsteroidal anti-inflammatory treatment. A European literature review. Pharmacoeconomics. 2001;19 Suppl 1:1–15.